CLL at ASH 2014: Expert discussion

Examining cell-free DNA provides non-invasive detection of malignancies in Hodgkin lymphoma

Best of ASH 2014

ASH 2014: Highlights in CLL from ASH 2014

Oprozomib shows potential in the treatment of multiple myeloma

Busulfan exposure dose tested for MDS and AML

Ibrutinib as a single agent and in combination with dexamethasone showed anti-tumour activity in multiple myeloma

Hope for avoiding chemo in patients with Hodgkins lymphoma

Combination therapy for high-risk MDS? Not quite yet

Should young adults with acute lymphocytic leukaemia receive paediatric treatment protocols?

Results of HD2000 trial comparing combination therapies in advanced-stage Hodgkin's lymphoma

Characterising the findings of the peripheral T-cell lymphoma registry

ASH 2014: Highlights in mantle cell lymphoma

ASH 2014: Highlights in multiple myeloma

Tyrosine kinase inhibitor in combination with chemo shows benefit in acute myeloid leukaemia

Chemo-free approach using IDH2 inhibitor shows positive response in acute myeloid leukaemia

New cytarabine combinations could overcome toxicities in AML treatment

Paediatric leukaemia treatment regimens lead to improved outcomes in adolescents and young adults

Targeted therapy effective in elderly patients with Philadelphia-positive acute lymphocytic leukaemia

First randomised evidence for benefit from adding a tyrosine kinase inhibitor in acute myeloid leukaemia

Children with rare leukaemia have better-than-expected outcomes after tailored treatment

Chemo-free treatment approach demonstrates positive responses in leukaemia patients

Compound improves survival in aggressive acute myeloid leukaemia with manageable added toxicity in phase III trial

Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma

Nivolumab shows early promise in Hodgkin lymphoma

Blinatumomab demonstrates significant clinical activity in residual ALL

New immunotherapy compound effective, safe in ALL patients with minimal residual disease

T cell therapy leading to prolonged remission for children with aggressive leukaemia

Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

ASH 2014: Expert discussion on the latest in AML

Pembrolizumab may bring hope for patients with Hodgkin lymphoma

Immunology highlights from ASH 2014

Comment: T cell therapy for children with aggressive leukaemia

Comment: Blinatumomab for acute lymphocytic leukaemia

Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma

ASH 2014: Expert discussion on the latest in CLL

Engineering stem cell resistance to HIV for two-pronged approach to HIV-associated lymphoma

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma

Investigational antibody demonstrates efficacy, safety for patients with aggressive multiple myeloma in phase I study

HIV-associated lymphoma responds well to stem cell transplantation

Relapsed multiple myeloma responds to combination therapy with daratumumab

Daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat multiple myeloma in phase I study

Stem cell transplantation safe for patients with HIV-associated lymphoma

Carfilzomib represents potent, effective addition to standard multiple myeloma therapy in phase III study

Post-transplant survival boosted by brentuximab vedotin in lymphoma

Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma patients in phase III study

Children with aggressive leukaemia experiencing remission with T cell therapy

ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy